Lung cancer is one of the top three cancers in terms of incidence and mortality in China, and the NCCN (National Comprehensive Cancer Network) guidelines currently recommend the use of concurrent radiotherapy as the standard treatment for limited small cell lung cancer and limited advanced non-small cell lung cancer. Numerous studies have shown that combined radiotherapy and chemotherapy are superior to radiotherapy and chemotherapy alone, and that concurrent radiotherapy is superior to sequential radiotherapy. However, the use of different chemotherapy regimens will undoubtedly have an impact on clinical outcomes. The NCCN recommends EP (cisplatin/etoposide) as the standard chemotherapy regimen for limited small cell lung cancer and EP or TP (paclitaxel/cisplatin) for limited advanced non-small cell lung cancer. The advantages of simultaneous radiotherapy for lung cancer: 1. enable the same irradiation dose to obtain higher tumor cell killing rate than radiotherapy alone; 2. cisplatin can increase the DNA damage induced by radiotherapy and inhibit the repair of sub-lethal damage in tumor cells, and etoposide itself can also induce DNA double-strand breaks and kill more tumor cells. 3. Cellular kinetic disturbances, i.e., an increase in the proportion of cells in the proliferative state and cell cycle-sensitive phase, increase the tumor-killing effect of radiation; 4. Decreased tumor volume and improved blood supply lead to reoxygenation and repair, increased sensitivity to radiotherapy and chemotherapy, and increased drug transport and uptake. 5.Synchronous radiotherapy can both suppress primary lesions and simultaneously kill potential distant subclinical metastatic lesions. One study showed that synchronous radiotherapy increased the median survival of advanced lung cancer by 10 months and improved the overall survival rate by 6%; however, the price paid for these advances is an increase in the incidence and severity of toxic reactions in normal tissues, which for lung cancer are most commonly radiation pneumonia and esophagitis. The incidence of grade 3 and 4 radiation pneumonitis and pulmonary fibrosis with conventional simultaneous radiotherapy is 25-30%. For this reason, we have been exploring: whether there are more advanced radiotherapy methods that improve survival rates while also reducing radiation damage to normal tissues surrounding the lungs. TOMO is an image-guided radiotherapy system that uses the same source of radiotherapy irradiation as CT to focus the radiotherapy dose on the tumor site and significantly reduce the damage to the surrounding normal lung tissue and vital organs. It greatly improves the precision of radiation therapy, ensures that the lesion does not leave the target area during the treatment of lung cancer, reduces the irradiation volume of normal lung tissue, and significantly reduces complications and side effects. Preliminary studies at home and abroad have shown that the incidence of severe radiation pneumonia and esophagitis is significantly reduced with TOMO radiotherapy compared with 3D-adaptive radiotherapy and conventional radiotherapy, and the tumor local control rate and quality of life of lung cancer patients are improved.